Researchers have explored the potential of thymoquinone-loaded solid lipid nanoparticles to mitigate mitochondrial dysfunction and oxidative damage. This study is relevant because it involves 3-Nitropropionic acid (3-NP), a toxin that causes brain lesions similar to those in Huntington's disease. The focus is on the protective effects of thymoquinone, known for its antioxidant properties, when delivered via solid lipid nanoparticles.
This approach could help manage conditions where mitochondrial dysfunction is key, such as neurodegenerative diseases. While not directly treating Huntington's disease, it offers insights into addressing similar mitochondrial damage, providing potential avenues for future neuroprotective treatments (Ramachandran & Thangarajan, 2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar